biotech
Leukemia Drug May Treat Type-1 Diabetes
Filed in archive Drugs, Vaccines and Therapeutics by ruth on November 20, 2008
Leukemia Drug May Treat Type-1 Diabetes
Leukemia Drug Imatinib (Trade name: Gleevec) has been shown in animal trials to have potentials to prevent and even reverse type 1 diabetes.
[snip] they found that treating mice with Imatinib or a similar inhibitor drug for seven weeks before the onset of auto-immune (type 1) diabetes prevented development of the disease long after the treatment was stopped.

Only 20 per cent of the animals treated with Imatinib became progressively diabetic by 30 weeks of age, as opposed to 71 per cent of those who did not have the drug.

The majority of imatinib-treated mice remained non-diabetic at 50 weeks of age, suggesting that the short-term therapy had long-term effects on the development of diabetes.

The drug put 80 per cent of mice with existing disease into remission when mice were treated for eight to 10 weeks after disease onset.

These findings suggest that the cancer drug could be used to treat type 1 diabetes and, possibly, other auto-immune diseases. However, trials are needed to confirm whether the drug confers the same effect on humans.

Permalink: Leukemia Drug May Treat Type-1 Diabetes
Tags: leukemia  cancer  diabetes  imatinib  gleevec  drug  type+diabetes  treat+type 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/138333
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Leukemia Drug May Treat Type-1 Diabetes:

  • Currently 6.50/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 6.50 out of 2 vote(s) cast.
Subscribe
Share It
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!